PMID- 7638084
OWN - NLM
STAT- MEDLINE
DCOM- 19950913
LR  - 20190913
IS  - 0270-4137 (Print)
IS  - 0270-4137 (Linking)
VI  - 27
IP  - 2
DP  - 1995 Aug
TI  - In vitro propagated dendritic cells from prostate cancer patients as a component 
      of prostate cancer immunotherapy.
PG  - 63-9
AB  - T cell-mediated cancer immunotherapy requires efficient antigen-presenting cells. 
      Dendritic cells (DCs) are arguably the most efficient antigen-presenting cells 
      studied to date. Individuals with prostate cancer often undergo various therapies 
      which may compromise their immune system, including the state of their DC 
      precursors. We report the in vitro propagation of DCs from peripheral blood of 
      patients with prostate cancer, most of whom are in clinical stages D1 or D2 and 
      have undergone radiation therapy. After 7 days in culture, the number of DCs 
      recovered were 20-50-fold higher than those isolated directly from peripheral 
      blood. This number is comparable to findings of previous studies with healthy 
      individuals. Cultured patients' DCs were capable of presenting tetanus toxoid to 
      autologous T cells in vitro. Furthermore, T cells from 2 of 4 patients 
      proliferated when cultured with their DCs and the lysate of a human prostate 
      cancer cell line (LNCaP), demonstrating the potential role of autologous DCs in 
      prostate cancer immunotherapy studies.
FAU - Tjoa, B
AU  - Tjoa B
AD  - Pacific Northwest Cancer Foundation, Cancer Research Division, Northwest 
      Hospital, Seattle, Washington 98125, USA.
FAU - Erickson, S
AU  - Erickson S
FAU - Barren, R 3rd
AU  - Barren R 3rd
FAU - Ragde, H
AU  - Ragde H
FAU - Kenny, G
AU  - Kenny G
FAU - Boynton, A
AU  - Boynton A
FAU - Murphy, G
AU  - Murphy G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Prostate
JT  - The Prostate
JID - 8101368
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigen Presentation/*immunology
MH  - Cells, Cultured
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Immunity, Cellular
MH  - Immunotherapy/*methods
MH  - Leukocytes, Mononuclear
MH  - Male
MH  - Middle Aged
MH  - Prostatic Neoplasms/*therapy
MH  - T-Lymphocytes/immunology
EDAT- 1995/08/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1995/08/01 00:00
PHST- 1995/08/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1995/08/01 00:00 [entrez]
AID - 10.1002/pros.2990270202 [doi]
PST - ppublish
SO  - Prostate. 1995 Aug;27(2):63-9. doi: 10.1002/pros.2990270202.